Dapagliflozin reduces systemic inflammation in patients with type 2 diabetes without known heart failure.
Wang DD, Naumova AV, Isquith D, Sapp J, Huynh KA, Tucker I, Balu N, Voronyuk A, Chu B, Ordovas K, Maynard C, Tian R, Zhao XQ, Kim F.
Wang DD, et al. Among authors: zhao xq.
Cardiovasc Diabetol. 2024 Jun 7;23(1):197. doi: 10.1186/s12933-024-02294-z.
Cardiovasc Diabetol. 2024.
PMID: 38849829
Clinical Trial.